Traded Nov 17, 2025 · filed 3 days later
Derivative exercise or conversion — not an open-market buy.
Loading…
Traded Nov 7, 2025 · Filed Nov 8, 2025
The CFO of Lenz Therapeutics paid $50K out of pocket for Lenz Therapeutics shares. 1 other person at Lenz Therapeutics bought some too, in the same month. The Lenz Therapeutics shares held grew by 68%.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell
open market purchase
Code P — open-market or private purchase
~$49,563
Shares × reported transaction price
$25K–$100K
+67.9%
Purchase shares ÷ estimated pre-transaction holdings, from the filing
Not enough history to judge
Confirmed open-market purchases by the same insider in the available history
2 distinct insiders in 30 days
Distinct insiders at the same issuer with confirmed open-market purchases
2 days after results of Nov 5, 2025, 61 days before results of Jan 7, 2026
Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results
None found in footnotes
Only flagged when a footnote says so; never inferred
Traded Nov 17, 2025 · filed 3 days later
Derivative exercise or conversion — not an open-market buy.
Shawn Olsson (Chief Commercial Officer) sold ~$108K of Lenz Therapeutics
Scheduled in advanceShawn Olsson (Chief Commercial Officer) sold ~$153K of Lenz Therapeutics
Scheduled in advance